Moderna, Inc. (NASDAQ: MRNA) has seen its stock price more than double over the past month, driven by a pivotal clinical development announcement. The company, in collaboration with Merck & Company, Inc (NYSE: MRK), reported a positive Phase 3 result for intismeran autogene, a personalized mRNA cancer therapy.
The stock jumped nearly 177% on August 19, 2026, following the announcement that the trial met its primary recurrence-free-survival endpoint and a key secondary endpoint measuring distant metastasis-free survival. This result marks Moderna's first Phase 3 validation for an mRNA-based cancer therapy.
The trial enrolled 1,137 patients with completely resected Stage IIB-IV melanoma. The study compared the personalized vaccine plus Merck’s Keytruda with Keytruda alone. Moderna CEO Stéphane Bancel described the result as an "extraordinary milestone" for the company and mRNA science.
Following the announcement, Moderna's shares surged roughly 158% over the past month, rising from around $62 in mid-August to approximately $160 on September 16, 2026. The article notes that while the clinical breakthrough is significant, investors are now focused on the next challenges.
These challenges include whether the melanoma result can become a commercially meaningful oncology franchise and whether Moderna can deliver the manufacturing, regulatory, and clinical follow-through required to justify the stock's higher valuation. The article highlights that commercializing personalized cancer vaccines presents a fundamentally different production challenge than mass-produced vaccines, requiring the ability to make thousands of patient-specific batches in parallel.
